Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

ASCO is kicking off its advocacy campaign in support of increased funding for federal cancer research. The launch of this year’s advocacy effort comes as Congress is beginning its work to craft Fiscal Year (FY) 2020 appropriations bills. As part of the campaign, ASCO is urging Congress to provide $41.6 billion to the National Institutes of Health (NIH) – a $2.5 billion increase from FY 2019 – and $6.5 billion to the National Cancer Institute (NCI).
ASCO recently urged Congress to work with the Administration to adopt high-quality pathways, reduce the administrative burden of utilization management practices, and other ideas to improve the quality of cancer care in the United States. The comments are in response to a request for information from the Chairman of the Senate Health, Education, Labor, and Pensions Committee on reducing health care costs.
“We strongly oppose the White House budget proposal for Fiscal Year (FY) 2020, which would stall our nation’s progress against cancer and impede access to needed care for the millions of Americans dealing with cancer. The proposal would make drastic, unprecedented cuts to the U.S. Department of Health and Human Services—which houses the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Centers for Medicare & Medicaid Services (CMS).
On February 28, ASCO joined the American Medical Association (AMA) and over 90 other groups in sending a letter to CMS urging them to provide guidance to Medicare Advantage (MA) plans on prior authorization processes.
 ASCO responded to a request for information (RFI) that the Senate Health Education, Labor and Pensions Committee issued in December to providers, insurers, and other groups to help identify specific ideas about how to reduce healthcare costs for consumers.  ASCO's response included the following: 
Unlike Medicare and private and commercial payers, Medicaid is not federally required to cover routine care costs (like physician visits and laboratory studies) for clinical trials, which means that Medicaid enrollees are less likely to participate in clinical trials. Members of Congress recently introduced bipartisan legislation, the CLINICAL TREATMENT Act (H.R. 913), to address this significant barrier to participation in clinical trials. Tell Congress to support the CLINICAL TREATMENT Act to improve the quality of cancer research and reduce disparities in cancer care.
WebMD recently recognized Karen M. Winkfield, MD, PhD, as its 2018 Advocate Health Hero for her efforts in working for equal access to high quality cancer care. Read more.
ASCO membership empowers you to be part of a larger voice advocating on behalf of the oncology profession to ensure that the real challenges facing oncology practices are taken into consideration by policymakers. You can get involved with the ASCO ACT Network and stay up-to-date with ASCO in Action on emerging government policies, regulations, and legal issues that may impact the practice of oncology. Learn more about the value of ASCO membership and gain what you need.